ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "85b513bd-d6cf-479e-b3db-df501fc03757"}, "_deposit": {"id": "2012364", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "2012364"}, "status": "published"}, "_oai": {"id": "oai:u-ryukyu.repo.nii.ac.jp:02012364", "sets": ["1642838338003", "1642838407795"]}, "author_link": [], "item_1617186331708": {"attribute_name": "Title", "attribute_value_mlt": [{"subitem_1551255647225": "Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)", "subitem_1551255648112": "en"}]}, "item_1617186419668": {"attribute_name": "Creator", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hama, Taketsugu", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nakanishi, Koichi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ishikura, Kenji", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Ito, Shuichi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nakamura, Hidefumi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Sako, Mayumi", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Saito-Oba, Mari", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Nozu, Kandai", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Shima, Yuko", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Iijima, Kazumoto", "creatorNameLang": "en"}]}, {"creatorNames": [{"creatorName": "Yoshikawa, Norishige", "creatorNameLang": "en"}]}]}, "item_1617186476635": {"attribute_name": "Access Rights", "attribute_value_mlt": [{"subitem_1522299639480": "open access", "subitem_1600958577026": "http://purl.org/coar/access_right/c_abf2"}]}, "item_1617186499011": {"attribute_name": "Rights", "attribute_value_mlt": [{"subitem_1522650717957": "en", "subitem_1522651041219": "Creative Commons Attribution 4.0 International License"}]}, "item_1617186609386": {"attribute_name": "Subject", "attribute_value_mlt": [{"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Mizoribine"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Frequently-relapsing nephrotic syndrome"}, {"subitem_1522299896455": "en", "subitem_1522300014469": "Other", "subitem_1523261968819": "Steroid-sensitive nephrotic syndrome"}]}, "item_1617186626617": {"attribute_name": "Description", "attribute_value_mlt": [{"subitem_description": "Background: Eighty percent of children with steroid-sensitive nephrotic syndrome (SSNS) relapse within 2 years and 40-50% patients show frequently-relapsing nephrotic syndrome (FRNS). Patients showing a relapse within 6 months after initial remission are at high risk of FRNS. Since frequent prednisolone treatment for FRNS induces severe prednisolone side effects, development of a treatment to prevent patients from shifting to FRNS is desirable. Mizoribine is an immunosuppressive drug with fewer side effects than prednisolone. Recent studies reported the efficacy of high-dose mizoribine in children with FRNS. Methods/design: We conduct a multicenter, open, randomized controlled trial to investigate the efficacy and safety of standard prednisolone plus high-dose mizoribine therapy in children with SSNS showing a relapse within 6 months after an initial remission. Patients are allocated to either standard prednisolone alone treatment group, or standard prednisolone plus high-dose mizoribine group. For the former group, mizoribine is administered at a dose of 10 mg/kg/day once daily and continued for 2 years. The primary endpoint is the duration to frequent relapse. Discussion: The results provide important data on use of high-dose mizoribine to prevent SSNS patients from shifting to FRNS. Since blood concentrations of mizoribine have not been investigated in detail until now, there is a possibility that mizoribine is underestimated in favor of other immunosuppressive drugs. In future, high-dose mizoribine therapy may lead to prevention of relapse in children at high risk of FRNS, and to decreased total dose of prednisolone.", "subitem_description_type": "Other"}, {"subitem_description": "論文", "subitem_description_type": "Other"}]}, "item_1617186643794": {"attribute_name": "Publisher", "attribute_value_mlt": [{"subitem_1522300295150": "en", "subitem_1522300316516": "Springer Nature"}]}, "item_1617186702042": {"attribute_name": "Language", "attribute_value_mlt": [{"subitem_1551255818386": "eng"}]}, "item_1617186783814": {"attribute_name": "Identifier", "attribute_value_mlt": [{"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/20.500.12000/45852"}]}, "item_1617186920753": {"attribute_name": "Source Identifier", "attribute_value_mlt": [{"subitem_1522646500366": "ISSN", "subitem_1522646572813": "1471-2369"}]}, "item_1617186941041": {"attribute_name": "Source Title", "attribute_value_mlt": [{"subitem_1522650068558": "en", "subitem_1522650091861": "BMC Nephrology"}]}, "item_1617187056579": {"attribute_name": "Bibliographic Information", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-09-10", "bibliographicIssueDateType": "Issued"}, "bibliographicVolumeNumber": "19"}]}, "item_1617258105262": {"attribute_name": "Resource Type", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_1617265215918": {"attribute_name": "Version Type", "attribute_value_mlt": [{"subitem_1522305645492": "VoR", "subitem_1600292170262": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_1617353299429": {"attribute_name": "Relation", "attribute_value_mlt": [{"subitem_1522306287251": {"subitem_1522306382014": "DOI", "subitem_1522306436033": "https://doi.org/10.1186/s12882-018-1033-z"}}, {"subitem_1522306287251": {"subitem_1522306382014": "DOI", "subitem_1522306436033": "https://doi.org/10.1186/s12882-018-1033-z"}}, {"subitem_1522306287251": {"subitem_1522306382014": "URI", "subitem_1522306436033": "http://creativecommons.org/licenses/by/4.0/"}}]}, "item_1617605131499": {"attribute_name": "File", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_access", "download_preview_message": "", "file_order": 0, "filename": "s12882-018-1033-z.pdf", "future_date_message": "", "is_thumbnail": false, "mimetype": "", "size": 0, "url": {"objectType": "fulltext", "url": "https://u-ryukyu.repo.nii.ac.jp/record/2012364/files/s12882-018-1033-z.pdf"}, "version_id": "1c334f56-03bd-464d-8f98-cd28181eca5f"}]}, "item_title": "Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)", "item_type_id": "15", "owner": "1", "path": ["1642838338003", "1642838407795"], "permalink_uri": "http://hdl.handle.net/20.500.12000/45852", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2020-05-21"}, "publish_date": "2020-05-21", "publish_status": "0", "recid": "2012364", "relation": {}, "relation_version_is_last": true, "title": ["Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)"], "weko_shared_id": -1}
  1. 学術雑誌論文
  2. その他
  1. 部局別インデックス
  2. 医学部

Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)

http://hdl.handle.net/20.500.12000/45852
http://hdl.handle.net/20.500.12000/45852
d4092ca1-967a-4e1c-8025-a7f8d44b926f
名前 / ファイル ライセンス アクション
s12882-018-1033-z.pdf s12882-018-1033-z.pdf
Item type デフォルトアイテムタイプ(フル)(1)
公開日 2020-05-21
タイトル
タイトル Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)
言語 en
作成者 Hama, Taketsugu

× Hama, Taketsugu

en Hama, Taketsugu

Search repository
Nakanishi, Koichi

× Nakanishi, Koichi

en Nakanishi, Koichi

Search repository
Ishikura, Kenji

× Ishikura, Kenji

en Ishikura, Kenji

Search repository
Ito, Shuichi

× Ito, Shuichi

en Ito, Shuichi

Search repository
Nakamura, Hidefumi

× Nakamura, Hidefumi

en Nakamura, Hidefumi

Search repository
Sako, Mayumi

× Sako, Mayumi

en Sako, Mayumi

Search repository
Saito-Oba, Mari

× Saito-Oba, Mari

en Saito-Oba, Mari

Search repository
Nozu, Kandai

× Nozu, Kandai

en Nozu, Kandai

Search repository
Shima, Yuko

× Shima, Yuko

en Shima, Yuko

Search repository
Iijima, Kazumoto

× Iijima, Kazumoto

en Iijima, Kazumoto

Search repository
Yoshikawa, Norishige

× Yoshikawa, Norishige

en Yoshikawa, Norishige

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利情報
言語 en
権利情報 Creative Commons Attribution 4.0 International License
主題
言語 en
主題Scheme Other
主題 Mizoribine
主題
言語 en
主題Scheme Other
主題 Frequently-relapsing nephrotic syndrome
主題
言語 en
主題Scheme Other
主題 Steroid-sensitive nephrotic syndrome
内容記述
内容記述タイプ Other
内容記述 Background: Eighty percent of children with steroid-sensitive nephrotic syndrome (SSNS) relapse within 2 years and 40-50% patients show frequently-relapsing nephrotic syndrome (FRNS). Patients showing a relapse within 6 months after initial remission are at high risk of FRNS. Since frequent prednisolone treatment for FRNS induces severe prednisolone side effects, development of a treatment to prevent patients from shifting to FRNS is desirable. Mizoribine is an immunosuppressive drug with fewer side effects than prednisolone. Recent studies reported the efficacy of high-dose mizoribine in children with FRNS. Methods/design: We conduct a multicenter, open, randomized controlled trial to investigate the efficacy and safety of standard prednisolone plus high-dose mizoribine therapy in children with SSNS showing a relapse within 6 months after an initial remission. Patients are allocated to either standard prednisolone alone treatment group, or standard prednisolone plus high-dose mizoribine group. For the former group, mizoribine is administered at a dose of 10 mg/kg/day once daily and continued for 2 years. The primary endpoint is the duration to frequent relapse. Discussion: The results provide important data on use of high-dose mizoribine to prevent SSNS patients from shifting to FRNS. Since blood concentrations of mizoribine have not been investigated in detail until now, there is a possibility that mizoribine is underestimated in favor of other immunosuppressive drugs. In future, high-dose mizoribine therapy may lead to prevention of relapse in children at high risk of FRNS, and to decreased total dose of prednisolone.
内容記述
内容記述タイプ Other
内容記述 論文
出版者
言語 en
出版者 Springer Nature
言語
言語 eng
資源タイプ
資源タイプ journal article
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
出版タイプ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
識別子
識別子 http://hdl.handle.net/20.500.12000/45852
識別子タイプ HDL
関連情報
識別子タイプ DOI
関連識別子 https://doi.org/10.1186/s12882-018-1033-z
関連情報
識別子タイプ DOI
関連識別子 https://doi.org/10.1186/s12882-018-1033-z
関連情報
識別子タイプ URI
関連識別子 http://creativecommons.org/licenses/by/4.0/
収録物識別子
収録物識別子タイプ ISSN
収録物識別子 1471-2369
収録物名
言語 en
収録物名 BMC Nephrology
書誌情報
巻 19, 発行日 2018-09-10
戻る
0
views
See details
Views

Versions

Ver.1 2022-02-02 02:07:02.429716
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3